Clinical trials: Type1 Diabetes Mellitus
Type 1 Diabetes Mellitus
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
- Trial name
- NCT03162926
- Testing
- VC-02 Combination Product (aka PEC-Direct)
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- ViaCyte
Type 1 Diabetes Mellitus
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.
- Trial name
- NCT00939289
- Testing
- Continuous Glucose Monitoring
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- DexCom, Inc.
T1D, Type 1 Diabetes (T1D)
Evaluation of a Biopsychosocial System
The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D).
- Conditions
- T1D, Type 1 Diabetes (T1D), Type 1 Diabetes
- Trial name
- NCT07440108
- Testing
- Use of Biopsychosocial Sensing System
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
To evaluate non-inferiority in the efficacy of HMR1964 as compared with Insulin lispro in terms of the change in HbA1C from baseline to endpoint. To compare the safety of HMR1964 with insulin lispro.
- Trial name
- NCT00290979
- Testing
- insulin glulisine
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 (insulin degludec) in Japanese subjects with type 1 diabetes.
- Trial name
- NCT01135927
- Testing
- insulin degludec, insulin detemir
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type I Diabetes
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's human insulin and isophane insulin compared with the Novo Nordisk's yeast based human insulin products (marketed in USA) in…
- Trial name
- NCT01308437
- Testing
- Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
- Where
- 25 sites in United States, India
- Volunteers
- 134 people
- Sponsor
- Wockhardt
Diabetes, Diabetes Mellitus, Type 1
A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes
BioChaperone Combo is a liquid formulation containing both Insulin Glargine and Insulin Lispro. The aim of this trial is to assess the efficacy and safety of BioChaperone® Combo in subjects with type 1 diabetes under a dose of…
- Trial name
- NCT01981031
- Testing
- BioChaperone® Combo, Humalog® Mix25
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 1
PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients
Primary objectives: To demonstrate biosimilarity with regard to the total and maximum pharmacokinetic exposure during one dosing interval (AUC ins. 0-24h, Cins.
- Trial name
- NCT04236895
- Testing
- Gan & Lee Insulin Glargine Injection
- Where
- 2 sites in Germany
- Volunteers
- 114 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 1
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin.
- Trial name
- NCT03449433
- Testing
- LY900014, Insulin Lispro, Insulin Aspart
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM.
- Trial name
- NCT02691247
- Testing
- CLBS03 Low Dose, CLBS03 High Dose
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- Lisata Therapeutics, Inc.
Type 1 Diabetes Mellitus
Pediatric Diabetics Type 1 Using InsuPatch
This study is a prospective, single-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is…
- Trial name
- NCT01368978
- Testing
- InsuPatch
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Insuline Medical Ltd.
Type 1 Diabetes Mellitus
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of subcutaneously administered teplizumab in adults with relatively recent onset T1DM, greater than 12 weeks and…
- Trial name
- SUBCUE (NCT01189422)
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus
A randomized single-blind study with the use of different lancing devices equipped with personal lancets to determine and to compare the amount of capillary blood volume and perceived pain after a single lancing of the fingertip.
- Trial name
- NCT04253431
- Testing
- Droplet lancing device (HTL-Strefa S.A.), Microlet 2 lancing device (Bayer), OneTouch Delicia lancing device (LifeScan)
- Volunteers
- 60 people
- Sponsor
- HTL-Strefa S.A.
Diabetes Mellitus, Type 1
Insulin Glulisine, Diabetes Mellitus Type 1
To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy
- Trial name
- NCT00397553
- Testing
- Insulin glulisine
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00751842
- Testing
- rhGAD65
- Where
- 43 sites in United States
- Volunteers
- 331 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
PS230005 Control-IQ 1.5 Post-Approval Study
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to <6 years old.
- Trial name
- NCT06717451
- Testing
- Control-IQ Technology v1.5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
In Clinic Evaluation of the PLGM Feature
This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.
- Trial name
- PLGM (NCT02130284)
- Testing
- Predictive Low Glucose Management Feature in Insulin pump
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Medtronic MiniMed, Inc.